Form 4: Vanda Pharmaceuticals CEO Acquires 20,000 Shares
SEC Form 4 Filing
Vanda Pharmaceuticals' CEO, Mihael Hristos Polymeropoulos, purchased 20,000 shares of common stock at an average price of $4.2236 on May 16, 2025.
Summary
- On May 16, 2025, Mihael Hristos Polymeropoulos, the President and CEO and Chairman of the Board of Vanda Pharmaceuticals Inc., acquired 20,000 shares of VNDA common stock.
- The shares were purchased at a weighted average price of $4.2236 per share, with individual transactions ranging from $4.22 to $4.23.
- Following the transaction, Polymeropoulos directly owns 2,315,731 shares of Vanda Pharmaceuticals Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a positive signal, but the document itself is simply a regulatory filing.
Positives
- The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Insiders purchasing company stock is generally viewed positively, as it aligns management's interests with those of shareholders. It can signal confidence in the company's future performance.
Stakeholder Impact
- The CEO's increased stake could reassure shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of the transaction: CEO purchased 20,000 shares of VNDA. |
| 05/19/2025 | Date of signature on the Form 4 filing. |
Keywords
Vanda Pharmaceuticals, VNDA, Mihael Hristos Polymeropoulos, CEO, share purchase, Form 4, beneficial ownership, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.